Legal Opinion
Kiossovski v. Forest Labs., Inc. (In re Celexa & Lexapro Mktg. & Sales Practices Litig.)
District Court, District of Columbia
Decided January 2, 2018No. MDL No. 09–02067–NMG; Civil Action No. 14–13848–NMGPublished
1Opinion of the Court
GORTON, United States District Judge
This case arises out of the marketing and sales of the anti-depressant drugs Celexa and Lexapro by defendants Forest Laboratories, Inc., Forest Laboratories, LLC and Forest Pharmaceuticals, Inc. (collectively, "defendants" or "Forest"). Plaintiffs Delana Kiossovski and Renee Ramirez (collectively, "plaintiffs") allege that defendants 1) engaged in a fraudulent marketing scheme designed to induce consumers to purchase Celexa and Lexapro for pediatric use in violation of the Racketeer Influenced and Corrupt Organizations Act ("RICO"), 18 U.S.C. §§ 1962(c) and…
2Cases cited8 opinions
- Phinney v. Wentworth Douglas HospitalCourt of Appeals for the First Circuit · 1999
- Powershare, Inc. v. Syntel, Inc.Court of Appeals for the First Circuit · 2010
- In Re Grand Jury Proceedings (Violette)Court of Appeals for the First Circuit · 1999
- Harbor Houses Condominium Ass'n v. IDC Clambakes, Inc.Court of Appeals for the First Circuit · 2013
- In Re Grand Jury ProceedingsCourt of Appeals for the First Circuit · 2005
3 more not listed; retrieve them via the Exa API.